Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment

Completed

• Conditions: Chronic Myeloid Leukemia; Newly Diagnosed
• Interventions: Drug: Imatinib

• Registration Number: NCT00632255
• Lead Sponsor: Imperial College London

Brief Summary

Imatinib has revolutionised the treatment of chronic myeloid leukaemia (CML). The first clinical trials were conducted in 1998 in patients with advanced disease, and by 2002 imatinib was established as the standard therapy for all patients including those recently diagnosed. In spite of overwhelming evidence about its efficacy we still need to gain more knowledge about issues related to long term treatment with imatinib such as why some patients respond better than others, the development of side effects and the quality of life.

Detailed Description

We plan to follow prospectively a cohort of CML patients in order to study their compliance to therapy,pharmacological levels of imatinib and the prevalence of side effects. We expect to be able to correlate the actual dose received, the pharmacological levels of drug in blood, with the change in the level of residual disease (measured by Q-PCR) at various time points. We also want to gain insight into the relationship between compliance to therapy and specific side effects and between compliance and duration of treatment. We will also assess the adherence to imatinib therapy after increases in the drug dose that are part of standard treatment.

Study Timeline

• Study Start: 2008-01
• Study First Submitted: 2008-02-29
• Study First Submitted QC: 2008-03-07
• Study First Posted: 2008-03-10
• Primary Completion: 2009-05
• Study Completion: 2009-05
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-03
• Last Update Posted: 2019-07-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

• Patients with CML who have been treated with imatinib (Glivec®) within 6 months of diagnosis as first line therapy. Initial therapy with hydroxyurea is permitted.

Exclusion Criteria

• Unable to give consent.
• Unable to communicate with the medical and nursing staff

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
1	Imatinib	Patients with CML who have been treated with Imatinib (Glivec) within 6 months of diagnosis as first line therapy. Initial therapy with Hydroxyurea is permitted

Trial Locations

Locations (1)

Haematology Department. Catherine Lewis Centre. Hammersmith Hospital. Du Cane Road.; 🇬🇧 London, United Kingdom